Analyst

Check for updates

Cite this: Analyst, 2023, 148, 618

Received 22nd July 2022, Accepted 12th December 2022 DOI: 10.1039/d2an01205g

rsc.li/analyst

1. Introduction

As a commensal microorganism Staphylococcus aureus does not normally cause harm to a healthy individual. Complications arise however with tissue damage¹ and a weakened immune system unable to fight off an opportunistic infection, for example in critically ill patients.^{2,3} Rapid and early detection of S. aureus is critical to diagnose infection,

^aDivision of Immunology, Immunity to infection & Respiratory Medicine, Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK ^bInstitut Necker-Enfants Malades, Paris, France

^dHerman B Wells Center for Pediatric Research, Pediatric Pulmonology, Allergy, and Sleep Medicine, Indiana University School of Medicine, Indianapolis, USA ^eService de Pneumo-Pédiatrie. Université René Descartes. Hôpital Necker-Enfants Malades, Paris, France

^fHôpital Foch, Exhalomics, Département des maladies des voies respiratoires, Suresnes. France

^gNIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Education and Research Centre, Wythenshawe Hospital, Manchester, M23 9LT, UK. E-mail: stephen.fowler@manchester.ac.uk

†Electronic supplementary information (ESI) available. See DOI: https://doi.org/ 10.1039/d2an01205g

Volatile metabolites differentiate air-liquid interface cultures after infection with Staphylococcus aureus*

Wagar Ahmed, 🕩 ^a Emmanuelle Bardin, ^{b,c} Michael D. Davis, ^d Isabelle Sermet-Gaudelus,^{b,e} Stanislas Grassin Delyle ^{(b,c,f} and Stephen J. Fowler ^{(b,a,g})

Early detection of lung infection is critical to clinical diagnosis, treatment, and monitoring. Measuring volatile organic compounds (VOCs) in exhaled breath has shown promise as a rapid and accurate method of evaluating disease metabolism and phenotype. However, further investigations of the role and function of VOCs in bacterial-host-stress response is required and this can only be realised through representative in vitro models. In this study we sampled VOCs from the headspace of A549 cells at an air-liquid interface (ALI). We hypothesised VOC sampling from ALI cultures could be used to profile potential biomarkers of S. aureus lung infection. VOCs were collected using thin film microextraction (TFME) and were analysed by thermal desorption-gas chromatography-mass spectrometry. After optimising ALI cultures, we observed seven VOCs changed between A549 and media control samples. After infecting cells with S. aureus, supervised principal component-discriminant function analysis revealed 22 VOCs were found to be significantly changed in infected cells compared to uninfected cells (p < 0.05), five of which were also found in parallel axenic S. aureus cultures. We have demonstrated VOCs that could be used to identify S. aureus in ALI cultures, supporting further investigation of VOC analysis as a highly sensitive and specific test for S. aureus lung infection.

> prescribe the right antibiotic at the right time, and reduce the risks associated with drug-resistant strains.4

> Measuring exhaled volatile organic compounds (VOCs) offers potential for rapid non-invasive detection of lung infection.^{5,6} To this end, several studies have explored VOC analysis with S. aureus infection from respiratory samples.7-9 However, VOCs from complex samples may contain several endogenous (e.g., host tissues and metabolism) and exogenous (e.g., sampling apparatus, environment, and other pathogens) sources, and these may likely confound VOCs directly associated with microbes. Investigating how these sources impact changes in the volatilome may provide novel insights into their metabolic pathway activation and role in infection pathogenesis. For example, studies have explored how changing the culture media environment can cause variations in the volatilome of bacterial cultures.^{10,11} Confounders such as host response metabolic response to an infection may be responsible for poor reproducibility between in vitro and in vivo studies.12,13

> Infection models of microbes and mammalian cells are more representative of the human lung environment than standard microbial cultures.^{14,15} Air-liquid interface (ALI) culture models are widely used to emulate the cellular structure of lung disease in controlled environments and in



View Article Online

PAPER

^cUniversité Paris-Saclay, UVSQ, INSERM, Infection et inflammation, Montigny le Bretonneux. France

Analyst

some cases reduce the dependence on animal models for experimentation.¹⁶ Studies have also profiled the headspace from air-liquid interface (ALI) models, to investigate viral infection and the metabolic impact of oxidative stress from smoking.^{17–19} These studies used either used stir-bar sorptive extraction or solid phase microextraction to sample VOCs from modified cell culture apparatus. All three studies used gas chromatography-mass spectrometry (GC-MS) for analysis of VOCs.

The aim of this study was to model epithelial damage caused by *S. aureus* and analyse the volatilome for potentially diagnostic biomarkers for *S. aureus*. The hypothesis was that VOC sampling could be used to profile potential biomarkers of *S. aureus* lung infection. We developed a method to sample VOCs using thin-film microextraction (TFME) from the apical compartment of an alveolar epithelial ALI culture, analysed offline by thermal desorption-gas chromatography-mass spectrometry (TD-GC-MS). Univariate and multivariate statistical comparisons will be presented between mammalian cells with and without *S. aureus* inoculation, using cell culture media and *S. aureus* culture as control samples.

2. Methods

2.1. Strains and cell culture

The immortalised A549 alveolar epithelial cell line was used in this study, kindly donated from the Blaikley lab at the University of Manchester (passage no. 117). Cells were cultured in Dulbecco's Modified Eagle's medium (DMEM) supplemented with 4500 mg L⁻¹ glucose (Sigma Aldrich, UK), 10% fetal bovine serum (PAA, UK), 2% 200 mM L-glutamine (Sigma Aldrich, UK), 1% 100 mM sodium pyruvate solution (Sigma Aldrich, UK), 1% penicillin–streptomycin (1000 μ g mL⁻¹–10 mg mL⁻¹ in solution with 0.9% NaCl, Sigma Aldrich, UK), and 0.1% 250 μ g mL⁻¹ Amphotericin B (Gibco, UK).

Cells were incubated at 37 °C in 5% CO₂, passaged when at least 80% cell confluence was reached using trypsin-EDTA (0.25% solution, Sigma Aldrich, UK), centrifuged at 100 RCF for 5 min, and the pellet resuspended in fresh media to a concentration of 1×10^6 cells per mL. Cell concentration was determined using a trypan blue stain (0.4%, Sigma Aldrich, UK) and cells counted using a Fuchs-Rosenthal haemocytometer (C-chip DHC-F01, NanoEntek, South Korea).

To generate an ALI culture, approximately 1×10^5 cells were seeded onto sterile 12-well plates with well inserts (ThinCertTM, PET transparent membrane, pore size 3.0μ m, pore density 0.6×10^6 cm², insert surface area 113.1mm², Gibco, UK). Spent media in the apical compartment was removed after 24 h to generate a cell layer exposed to air on the apical side of the insert membrane. Basal compartment media was replenished every other day. Cell growth was visually inspected compared with control wells. In addition, transepithelial electrical resistance (TEER) measurements were carried out using an epithelial voltohmmeter according to manufacturer protocols (EVOM², World Precision Instruments, USA). Cell monolayer TEER was calculated using the following equation: TEER (Ω cm²) = $R_{\text{Tissue}} \times S$, where *R* is resistance (Ω), $R_{\text{Tissue}} = R_{\text{blank}} - R_{\text{culture}}$, and *S* is the insert surface area (cm²). Both apical and basal compartments were washed with phosphate buffered saline (PBS) before measurement.

2.2. Infection with S. aureus and VOC sample collection

A reference strain of *S. aureus* (ATCC 29213) was initially subcultured in tryptic soy media. Apical compartments were inoculated with 100 μ L of *S. aureus* suspended in PBS and incubated for 24 h at 37 °C. Prior to this, basal media was replaced with DMEM without antibiotic supplementation and incubated at 37 °C for a further 24 h to confirm absence of contamination.

TFME was carried out using PDMS strips (20 mm × 15 mm × 0.45 mm, Goodfellow Cambridge Ltd, Huntingdon, UK), as previously described.²⁰ Strips were initially washed with water then methanol and conditioned in a stream of N2 at 350 °C for 1 h. Conditioned strips were stored in capped stainless-steel tubes until sample collection and analysis and were used within 24 h of conditioning. Strips were reused after reconditioning with the same parameters. VOCs were sampled by inserting a PDMS strip into the apical compartment of each well insert. Cultures were then incubated for a further 24 h before removing PDMS strips for VOC analysis. S. aureus was aspirated from the apical side with a 100 µL PBS wash and growth observed on tryptic soy agar plates using the drop plate method (10 µL of the PBS wash dropped on a segment of the agar plate and incubated at 37 °C for 18 h). Basal media was also collected to observe S. aureus migration through the cell layer and insert membrane. The PBS wash and basal media were diluted (1:10) up to a maximum of four dilutions.

Absorbance change of Phenol Red, a pH indicator and a constituent of DMEM, was measured as an orthogonal method to detect cell culture acidification by *S. aureus* infection. A standard curve of DMEM at different pH was created by adding citric acid, measured at 415 and 560 nm (Biochrom Asys UVM340, Cambridge, UK). The standard curve was calculated based on the 415/560 nm ratio for Phenol Red and used to interpolate pH levels of basal media (R^2 0.96). This method was used as opposed to direct measurement using a pH probe due to the low volume of spent media available per well and risk of cross contamination between infected and uninfected samples.

2.3. Thermal desorption-gas chromatography-mass spectrometry (TD-GC-MS)

PDMS strips were dry purged with N_2 at 50 mL min⁻¹ for 4 min to remove excess water on the sorbent before analysis by TD-GC-MS. Prior to thermal desorption, a gas standard (1 ppmV *p*-bromofluorobenzene in N_2 ; Thames Restek, Saunderton, UK) was automatically spiked onto each tube. Tubes were then desorbed at 280 °C for 5 min (TD100, Markes International, Llantrisant, UK) then transferred with splitless injection to a cold trap (kept at 0 °C) for cryofocussing which was subsequently flash heated to 280 °C for 2 min. Desorbed

Paper

VOCs were transferred to the GC column (DB-5 ms, length 30 m × internal diameter 0.25 mm × film thickness 0.25 µm, Agilent Technologies, Cheadle, UK) using a constant helium flow of 1 mL min⁻¹. The GC column oven (7890B, Agilent Technologies, Cheadle, UK) was set to a linear temperature programme starting at 30 °C and increasing to 250 °C at 7.5 °C min⁻¹ (total GC cycle time of 29.33 min). After GC separation, VOCs were transferred to the MS (7010, Agilent Technologies, Cheadle, UK) where they were ionised (EI 70 eV) in the source kept at 150 °C. Data was acquired in full scan mode with an acquisition rate of 5 scans s⁻¹ between *m*/*z* 40–300. In addition, validation of cell culture VOCs was performed on a different GC-MS method, as described previously.²¹

2.4. Data analysis

Masshunter Quantitative Analysis software (version B.07.00, Agilent, Cheadle, UK) was used to automatically integrate peaks (Agile2) and identify VOCs in each sample to MSI level 2^{22} using the NIST mass spectral library (version 2014, match factor > 70) and retention indices calculated using an alkane ladder. An aligned $n \times p$ matrix was created of peak intensities. Missing values were imputed using Random Forest imputation (R package missForest). All samples were then normalised by the internal standard (p-bromofluorobenzene), and features were log transformed and mean centred (i.e. z-normalised). Statistical analyses were performed in Graphpad Prism (version 9.1) and R (v 4.1.1) and consisted of univariate tests including repeated measures ANOVA, non-parametric Mann-Whitney-U and multivariate analysis in the form of unsupervised principal component analysis (PCA) and supervised classification via principal component-discriminant function analysis (PC-DFA). PC-DFA was cross validated (80:20 training: test set) using stratified random sampling with 1000 repeats. Comparisons were made between culture media and

mammalian cells, and infected and uninfected cells. The Benjamini–Hochberg one way ANOVA was applied (q < 0.05) where appropriate to control the false discovery rate (FDR).

3. Results

3.1. Blank PDMS strip reproducibility

Reproducibility of PDMS strip adsorption was assessed by calculating RSD for the internal standard purged onto blank PDMS strips. Repeated desorption of a single blank PDMS strip (n =10) resulted in an RSD of 1.35% whereas ten repeat desorption runs of a tube without sorbent material resulted in an RSD of 1.10%. Desorption of several individual PDMS strips (n = 10) resulted in an RSD 7.27%. The most consistently produced compounds associated with the sorbent background were hexamethylcyclotrisiloxane and octamethylcyclotetrasiloxane.

3.2. Optimal ALI culture time and CFU inoculum for *S. aureus*

To assess the formation of a A549 cell layer on the well insert, transepithelial integrity was measured by TEER (n = 11) on day 2, 5, 7, 9, and 12 after seeding (Fig. 1). A repeated measures ANOVA showed TEER increased on all days compared to the initial measurement on day 2 (p = < 0.001), whereas no difference was found between days 5, 7, 9, and 12. Day 9 was selected as the optimal time to infect cells based on the representative TEER (55.2 ± 6.5) and low RSD (11.7%), in comparison to other time points (day 5 = 52.3 ± 14.2 RSD 27.2%, day 7 = 56.1 ± 16.8 RSD 30.0%, day 12 = 39.7 ± 3.6 RSD 9.1%). TEER measurements were also used to evaluate the impact of *S. aureus* on membrane integrity.

To select an infection CFU inoculum concentration for infection, A549 cells were cultured at ALI and the apical side




Fig. 1 Left: line graph with TEER measurements across several days on the same well inserts. Right: graph comparing three S. aureus CFU concentration of TEER fold change before and after inoculation.

was inoculated with *S. aureus* at three CFU concentrations – 1×10^3 , 1×10^4 , and 1×10^5 CFU (n = 3 per concentration). All *S. aureus* CFU concentrations decreased cell culture TEER after inoculation and incubation for 24 h (paired *t* test p < 0.001). Mean log fold changes for each CFU concentration were 1×10^3 CFU mL⁻¹ = 1.7, 1×10^4 CFU mL⁻¹ = 1.8, and 1×10^5 CFU mL⁻¹ = 1.8. No significant differences were found between TEER measured before or after inoculation between CFU concentrations (p > 0.05). The lowest concentration tested (10^3 CFU) was taken forward for infecting cells in the head-space sampling experiments. A low initial CFU was selected to reduce detection of saturated high-abundance VOCs from *S. aureus*, reducing the risk of sample carry over.

3.3. Volatiles from A549 cells without infection

Headspace volatiles were sampled from A549 cells and mediaonly controls after 9 days in ALI culture, under standard growth conditions without infection. In addition, a validation experiment was carried out using the same culture methods but with a different analytical method as described in²¹ (cells n = 6, media n = 3). All samples were confirmed free of microbial contamination after plate culture and visual inspection of the culture colour remaining red (media) or pink (cells) and absence of turbidity. After controlling for FDR, 107 features were significantly different between media and cells. For the validation experiment, 111 features were found significantly different between the two groups. Separation across PC1 was observed between sample groups for both original (Fig. 2A) and validation experiments (Fig. 2B).

Seven VOCs extracted from PCA loadings were significantly different between media and cells across both experiments as shown in Fig. 2. These included benzene 2-nitroethyl-(log 2 fold change [FC] 2.7, q < 0.001, validation experiment FC 5.2, q < 0.001), 1-hexanol 2-ethyl-(FC 2.0, q = 0.003 validation FC 2.3, q = 0.023) and a methylated furanone (Fig. 2C). The latter compound was identified as 2(3*H*)-furanone 5-methyl-(FC 2.5, q = 0.026) in the original experiment and as 2(3*H*)-furanone dihydro-4-methyl-(FC 2.9, q = 0.004) in the validation experiment. VOCs with a decreased abundance in cells (Fig. 2D) were benzeneacetaldehyde (FC -2.5, q = 0.003, validation FC -3.5, q = 0.001), benzaldehyde (FC -2.0, q = 0.003, validation FC -1.6 q = 0.007), 4-quinolinecarboxaldehyde (FC -8.1, q = 0.010, validation FC -1.2, q = 0.032, validation FC -2.7 q < 0.001).

3.4. Infection of A549 cells with S. aureus

After 9 days of maintaining an ALI, cells were infected with 10^3 CFU of *S. aureus* (n = 6) on the apical side alongside cells without infection inoculated with 100µL PBS without *S. aureus* (n = 6) and control samples (media and *S. aureus* in media). After 24 h, leakage of media from the basal to the apical side was observed for A549 cultures with *S. aureus* infection, whereas no such leakage was seen for samples uninfected with *S. aureus*. TEER measurements decreased in *S. aureus* infected cells after 24 h (paired *t* test p = 0.0003), as shown in Fig. 3A. Basal media pH suggested increased acidity in infected cell

cultures compared to uninfected cells (Fig. 3B) which is consistent with bacterial contamination of mammalian cell culture. No visible *S. aureus* growth was observed for A549 cultures alone compared to infected A549 for both apical and basal samples (Fig. 3C). Saturated microbial growth was observed across all inoculated cultures, including the basal compartment cultures (>10⁷CFU) suggesting exponential growth of *S. aureus* in the presence of A549 cells.

3.5. Volatile profile of A549 cells infected with S. aureus

Data were initially assessed using PCA (Fig. S1[†]) and inspecting total ion current chromatograms, where no clear separation was found between groups. In addition, two samples failed analysis due to water retention. Therefore, to extract VOC features which differentiate infected and uninfected cells, a cross-validated PC-DFA (with eight PCs) was performed with A549 cells infected with *S* aureus (n = 4) in comparison to uninfected A549 cells (n = 6), media (n = 8), and S. aureus (n = 8)samples alone (Fig. 4). The PC-DFA model showed separation across the first discriminant function (DF1, S3) between samples with A549 cells (infected and uninfected) and those without (media and S. aureus alone). The second discriminant function (DF2, S4) showed separation of infected and uninfected sample groups. After applying an arbitrary noise cut off to the loadings (0.05), features that contributed to separation were extracted for DF1 (n = 70) and DF2 (n = 50).

Features from DF2, which indicated differences between infected and uninfected cells (n = 34, Table 1), were screened using the univariate non-parametric Mann–Whitney-*U* test and 22 were found to have statistically significant changes in abundance between the two groups (Fig. 5). Two VOCs were decreased in infected cells compared to uninfected. All other features were significantly increased (n = 20), five of which were also increased in axenic *S. aureus* cultures (see Table 1).

4. Discussion

In this study, we found several VOCs associated with uninfected and infected alveolar epithelial cells in ALI cultures. VOCs were associated with the infection response alone and included VOCs also identified in axenic cultures of *S. aureus*. Therefore, these results demonstrate the diverse sources of VOCs in the infection process (*i.e.* bacterial infection and cell response) and are potentially good candidates as diagnostic biomarkers of the multiple contributors to infection pathogenesis.

An assessment of PDMS material adsorption showed good reproducibility without degradation after 10 sequential desorption cycles of the same PDMS strip. Desorption between different PDMS strips was less reproducible (higher RSD). This may be due to minor inconsistencies between strip length and width. To minimise the number of water-logged samples, the dry purge time would require optimisation in future studies. When sampling from cell headspace, only seven compounds were observed to be consistent between two experiments con-




Fig. 2 PCA scores plot showing PC1 and PC2 of headspace sampling experiments where VOCs were sampled after 24 h of incubation at 37 °C comparing (A) A549 and media, and (B) validation experiment comparing A549 and media using a different analysis method (see methods). *Z*-score plots of (C) of significantly increased (p < 0.05) VOCs in A549 and (D) significantly increased VOCs in media, across both original (E1) and validation (E2) experiments.

ducted at different times and with different GC-MS methods. This shows that different analytical methods can impact on the total number of VOCs observed. Furthermore, improving sampling and analytical parameters, such as introducing a secondary polar GC column, will increase the abundance and range of detectable VOCs. For sampling headspace, research-




Fig. 3 (A) TEER measurements per well before and after infection of A549 cells with *S. aureus*. (B) Basal media pH after 24 h of infection (A549-*S. aureus*) compared to uninfected (A549) cells. (C) Tryptic soy agar plates with serial dilutions (DF = estimated CFU mL⁻¹) of apical PBS wash and basal media from both sample groups.




Fig. 4 Cross-validated PC-DFA (PCs = 8) scores plot illustrating separation between sample groups on DF1 and DF2.

ers have developed multi-bed TFME films which may also increase the range of VOCs sampled from cultures.²³

Cells were successfully infected with *S. aureus* as demonstrated by increased CFU post-infection, reduced pH in coculture (*i.e.*, acidification due to aerobic bacterial contamination), and reduced TEER suggesting membrane damage. Epithelial damage by S. aureus and subsequent membrane rupture resulting in leakage in ALI culture is consistent with previous studies using a similar airway infection model.²⁴ Alcohol and fatty acid compounds were increased in the VOC profile of infected cells. Phenylethyl alcohol has previously been identified in S. aureus headspace.²⁵ The VOC 1-hexanol 2-ethyl in ALI culture was also shown by previous studies investigating A549 cells.²⁶ Fatty acids have been associated with the cell membrane phospholipid structure and their increased detection in infected cells may potentially be caused by membrane damage by S. aureus. Fatty acids are also found to control cell membrane integrity and biofilm dispersion in S. aureus.²⁷⁻³⁰ Aromatic volatiles were decreased under normal cell growth suggesting uptake from the media and have been reported in previous studies investigating A549 cells.^{26,31} Several methylated pyridine compounds were increased in infected cells compared to uninfected cells. Pyridine 3-methyl-2-phenyl was also detected in axenic S. aureus cultures. Pyridine is a potential marker for smoking and structurally associated with nicotine.32

Although it was expected that VOCs which are very volatile will not be captured by the PDMS sorbent, not all VOCs within the detectable range were consistent with previous literature. For example, dimethyl disulfide (DMDS), a VOC known to be emitted by *S. aureus*, was comparatively low in infected cells, which suggests altered metabolism during infection. Furthermore, DMDS is a ubiquitous VOC produced by several microbial and plant species and therefore has little value as a

 Table 1
 List of VOCs which differentiate infected and uninfected A549

Word frame (bork 1) mode mode </th <th>Out the legitime and the matrix the matr</th> <th></th> <th>Quantifier</th> <th>NIST match</th> <th>Retention</th> <th>NIST library</th> <th>Calculated</th> <th>Detected in infection</th> <th>Detected in S. aureus</th> <th>Normalised peak intensity</th> <th>ed peak</th> <th></th> <th>ł</th> <th></th> <th>95% CI</th> <th>95% CI</th>	Out the legitime and the matrix the matr		Quantifier	NIST match	Retention	NIST library	Calculated	Detected in infection	Detected in S. aureus	Normalised peak intensity	ed peak		ł		95% CI	95% CI
Tropication 10 51 344 71 60 534 71 700 535 730 731 730<	Treprindic 1 1 <t< th=""><th>VUC name (NIST ILI)</th><th>z/m</th><th>ractor</th><th>ume (min)</th><th>KI</th><th>KOVAUS KI</th><th>model</th><th>cultures</th><th>Mean</th><th>SD</th><th>Median</th><th></th><th></th><th>lower</th><th>upper</th></t<>	VUC name (NIST ILI)	z/m	ractor	ume (min)	KI	KOVAUS KI	model	cultures	Mean	SD	Median			lower	upper
	Tremonication Total	Twiothylamino	101	0 1 0	11 0	744	503			0.101	0.070	0 6 4 6		171	0000	1000
CryOpeneteral 7.1 0.0 0.00 0.000	Streptione 7,2 0,2,3 0,0,4 0,2,3 0,0,0 2,3,9 0,0,0				E.o.			•		101.0		01000				11.0
Cyrpaneted 74 99 338 NA 723 14 0.361 0.435 0.436 0.431 0.031 239 0.331 0.331 239 239 <th< td=""><td>Proprinter 71 99 338 NA 729 199 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05</td><td>z-Propenoic acid</td><td>7/</td><td>7.76</td><td>5.81</td><td>NA</td><td>17/</td><td></td><td></td><td>48C.U</td><td></td><td>860.0</td><td></td><td>010.0</td><td>000.2-</td><td>c/4.0-</td></th<>	Proprinter 71 99 338 NA 729 199 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05 136 0.05	z-Propenoic acid	7/	7.76	5.81	NA	17/			48C.U		860.0		010.0	000.2-	c/4.0-
Distriction T Total <	District T, mode Matrix	Propanoic acid	74	89.9	3.82	NA	722	<i>~</i>		0.566		0.00		0.010	-2.379	-1.397
Dialitidi, dimentivi anteriori Dimanuto, 2-diforo/N, 91 90 4.0 7.2 7.2 7.1 7.1 7.3 9.3 9.063 9.03<	Disufficie chartery ¹ is 30 and 201 203 200 203 203 203 203 203 203 203 203	2,2'-Bioxirane	57	81.9	3.94	NA	729			-0.330		0.370		0.610	-3.350	0.913
Imamulation 2, colinor My 107 81.0 4.20 7.30 7.31 1 7.00 3.200 0.301	Imanume 2-bilowovv 107 81.0 4.20 730 731 730 0.30 0.305 0.3	Disulfide, dimethyl ^a	94	90.6	4.10	722	740	\rightarrow		-0.190		0.436		0.010	2.031	2.991
		Ethanamine. 2-chloro-N.N-	107	87.0	4.29	750	753	• ←		0.349		0.629		0.038	-2.602	-0.085
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	dimethyl						-								
with the function of the product of the pr		2-Pronenoic acid. 2-methyl	86	71.1	4.63	711	776			-0.012	0.717	-0.015	-	010	0.347	1.935
remix end 0 7 3 6 1 0	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Aretyl valeryl	50	03.4	95 F	816	830	• ←		0 622		0.658		010	-7 296	-0.696
	Current control	Touris soid hudusids	60	1.00	0.00	OTO VIV	010	- •		77070				010	1 010	0000
Harmone, 3-Fortheyn, sterter 7 2.33 6.47 8.68 7.64 1.336 0.010 -2.337 0.037 1.337 0.037 1.336 0.037 1.336 0.037 1.336 0.037 1.336 0.037 1.336 0.037 1.336 0.037 0.037 0.037 0.037 0.037 0.037 0.036 1.337 0.037 0.037 0.036 1.337 0.037 0.036 1.337 0.033 1.337 0.033 1.336 0.036 1.337 0.037 0.036 1.337 0.037 1.336 0.037 1.336 0.037 0.356 0.066 1.337 0.037 0.356 0.066 1.337 0.037 0.356 0.066 1.337 0.037 0.356 0.066 1.332 0.337 1.337 0.337 1.367 0.036 1.366 0.337 1.366 0.337 1.366 0.337 1.366 1.366 0.337 1.366 1.366 1.366 1.366 1.366 1.366 1.366<	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		00	14.4	5.54 5.55	NA	049			100.0		0.00.0		010.0	016'T-	0000-
$ \ \ \ \ \ \ \ \ \ \ \ \ \ $	$ \begin{tabular}{ c c c c c c c c c c c c c c c c c c c$	Butanoic acid, 2-methyl	74	82.9	6.31	894	868			0.638		0.111		.171	-3.833	0.281
	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	1-Butanol, 3-methyl-, acetate	70	92.4	6.42	867	874	←		0.700		0.668		0.010	-2.187	-0.875
i + i + i + i + i + i + i + i + i + i +	i + i + i + i + i + i + i + i + i + i +	Cyclopent-4-ene-1,3-dione	96	84.3	6.47	880	876			0.584		0.131		0.352	-0.928	1.815
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$		4-Hentanol, 3.5-dimethyl	87	74.1	8.15	NA	958	~		-0.093		-0.303		010	-3.423	-1.378
		Furaneol	178	84 5	10 11	1097	1052	_		0 391		0.389		171	-0.201	2 563
Higher bench 20 11.2 11.3 0.039 0.030 0.041 0.052 0.046 0.053 0.046 0.066 1.066 1.066 0.033 0.041 0.033 0.046 0.046 0.046 0.046 0	$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Dhowdothyl alachal ^d	120	0.10	11.26	1005	1111	÷	÷	100.0		0 5 4 1		1010	107.0	1 676
3. Further-norm144114311431143114311430.0.230.0.2010.0.720.0.700.0.720.0.700.0.720.0.630.3653. Belydiomeic iscience34906112312.20NA11537791660.1310.0080.171-0.7522.9983. Chydiomyellyl2-rinding8289.113.221133110.038-1.3460.3650.3463. Chydiomyellyl2-rinding8289.113.22113312.2711341133-0.0660.7320.0380.017-0.0632.0382. Solvolvy, enly12071.214.4512.3012201220123316.90.016-0.6332.038Beroiz card, 2.lydroxy, enly12091.312.3212337-0.4920.7320.010-2.561-0.633Beroiz card, 2.lydroxy, enly12091.312377712230.010-2.561-0.6332.338Beroiz card, 2.lydroxy, enly12091.313377-0.4920.7380.010-2.561-0.533Beroiz card, 2.lydroxy, enly120133777123313377-0.4320.7370.010-2.561-1.735Beroiz card, 2.lydroxy, enly13314014331433143314331433143514314351431435Beroiz card, 2.lydroxy, enly231311337<	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $		9.L	4.00	-0.11	1100	7117			160.0		-0.J#1		010-0	-2.114 2.554	C/0.T-
		4H-Pyran-4-one, 2,3-dihydro-	144	79.8	11.97	1134	1143			0.239		0.201		.762	-0.664	1.982
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	3,5-dihydroxy-6-methyl														
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Dehydromevalonic lactone	54	90.6	12.22	1169	1155			0.154	1.144	-0.104		0.114	-3.150	0.365
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	2-Isobutyl-4-methylpyridine	107	90.3	12.27	1154	1158	←		0.469		0.440		0.038	-1.346	-0.038
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	owardidition: owardid	3-(2-Hvdroxvethvl)-2-	100	73.1	12.30	NA	1159			0.190	1.12.3	-0.2.2.9		171	-0.725	2.948
	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	o (= try utory cury -) = oxazolidinone														i
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	$ \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$		00	100	000	0001	1007							r.c.	0.000	0000
$ \begin{array}{rrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrrr$	Berzoic acid, 2-hydroxy, ethyl 120 7.1.2 14.45 12.37 7 7 0.343 1.068 0.732 1.252 0.001 -2.651 0.0534 etric acid, 2-hydroxy, ethyl 120 7.1.2 14.45 12.99 1270 7 7 0.353 1.088 0.752 1.851 0.101 -2.651 -0.355 ettic acid 4-chioro 139 9.13 15.60 NA 1337 0.138 0.561 0.076 0.588 0.610 -0.945 2.131 Berzoic acid, 4-chioro 139 9.13 15.60 NA 1337 0.138 0.561 0.078 1.651 0.171 -0.312 3.358 n-Decanoic acid 4-chioro 139 9.13 15.60 NA 1337 0.138 0.561 0.078 1.651 0.171 -0.312 3.358 n-Decanoic acid 4-chioro 139 9.13 15.60 NA 1337 0.529 0.805 0.763 0.888 0.610 -0.945 2.131 Berzoic acid, 4-chioro 139 0.371 0.112 0.639 0.771 0.010 -2.034 0.200 2(3H)-Furanone, 85 91.1 17.92 14.63 14.53 7 7 0.03 3.879 0.763 0.888 0.610 -0.945 2.131 0.500 (397) 1.64 0.000 -2.044 0.000 -2.044 0.000 -2.044 0.000 -2.044 0.000 -2.044 0.000 -2.044 0.000 -2.044 0.000 -2.044 0.000 -2.045 0.000 0.800 0.157 0.010 -2.045 0.000 -2.045 0.000 0.800 0.157 0.010 -2.045 0.000 -2.045 0.000 0.800 0.157 0.010 -2.045 0.000 -2.045 0.000 -2.045 0.000 0.800 1.154 0.010 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.044 0.000 -2.045 0.000 -2.044 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.044 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.04 -0.095 0.000 -2.044 0.000 -2.045 0.000 -2.044 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2.045 0.000 -2	Decanal	78	1.68	13.22	1200	C021			-0.086		0.0/8		/00/	-0.063	2.038
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Berrore actd, 2-hydrowy, ethyl 120 71.2 14.45 1249 1270 7 7 1 0.353 1.198 -0.187 2.122 0.010 -2.861 -1.857 eter acter indo 2 14.000 235 0.14.88 1292 1293 7 0.333 1.108 0.533 0.573 0.80 0.010 -1.739 0.335 1.358 0.563 0.88 0.561 0.0148 1.337 0.573 0.805 0.573 0.88 0.561 0.0143 1.333 0.575 0.575 0.858 0.575 0.805 0.573 0.805 0.573 0.805 0.573 0.805 0.573 0.805 0.573 0.805 0.573 0.805 0.501 -0.945 0.208 0.501 -0.945 0.208 0.575 0.805 0.575 0.805 0.573 0.805 0.501 -0.945 0.208 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.575 0.805 0.501 -0.945 0.208 0.575 0.805 0.575 0.805 0.575 0.805 0.501 -0.945 0.208 0.575 0.805 0.575 0.805 0.575 0.805 0.501 -0.945 0.500 0.202 0.500 0.517 0.1190 0.500 0.529 0.200 0.501 0.5	Benzenepropanenitrile	91	95.3	13.82	1243	1237	← ·		0.343		0.725		0.010	-2.631	-0.634
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	exterexterindoff9095.614.88129212937-0.4920.738-0.5031.5130.010-1.739-0.335Beroolc acid7385.516.1215.69NA13370.4181.265-0.0781.511-0.9353.538Beroolc acid7385.516.1214.8713370.4181.1020.5390.7470.010-1.739-0.280 $nSrPeranoic acid7387.516.1214.4514.4514.5371.1020.5390.7470.010-2.9380.2002(3P)+Pannone,8591.117.79214.465110.3000.7530.4101.9640.010-2.047-1.1442(3P)+Pannone,8591.117.79214.465770.4131.9640.010-2.674-0.9952(3P)+Pannone,8591.117.79214.46514.46514.4614.4650.171-0.0431.0290.247-1.1442(3P)+Pannone,8591.117.79214.46514.46514.650.4101.9640.010-2.674-1.4142(3P)+Pannone,8591.117.79214.46514.6514.5515.647-1.4142(3P)+Pannone,8510.914.9215.62770.4131.060.010-2.674-1.4142(3P)+Pannone,12991.514.5515.647$	Benzoic acid, 2-hydroxy-, ethyl	120	71.2	14.45	1249	1270	←	←	0.363	1.198	-0.187		0.010	-2.861	-1.857
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$ \begin{array}{l l l l l l l l l l l l l l l l l l l $	ester														
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	$Indole^{a}$	06	95.6	14.88	1292	1293	←		-0.492		-0.503		0.010	-1.739	-0.395
n-Decanoic acid7385.516.1213871361 0.529 0.805 0.763 0.888 0.610 -0.945 2.131 Benzeneschnide92 87.6 16.80 1412 1399 7 0.376 1.102 0.639 0.747 0.010 -2.938 -0.280 Senzeneschnide93 84.4 17.71 1446 1453 7 1 0.309 0.747 0.010 -2.938 -0.280 $2(3H)$ Framone, 85 91.1 17.92 1463 1453 7 7 0.100 1.054 0.010 -2.747 -1.140 5 -heyldihydro 85 91.1 17.92 1463 1453 1465 7 0 0.910 1.572 0.010 -2.747 -1.140 5 -heyldihydro 129 94.5 19.49 1492 1562 1564 7 0.93 1.572 0.010 -2.674 -0.999 $Cyclohesane, 1-ethenyl-1-9372.994.519.53156215621562156215621771.144Cyclohesane, 1-ethenyl-1-9372.994.51.1270.0102.574-0.999Cyclohesane, 1-ethenyl-1-9372.994.51.1230.0102.474-0.999Cyclohesane, 1-ethyle-1-19312912681730.10112680.1012.574-0.126Dodecanoic acid12972.9$	n-Decanoic acid7385.516.12138713610.5790.5390.8050.7630.8880.6100.9452.131Benzencentunde9287.616.8014121339770.0030.8770.1020.29380.2030Renzencentunde9287.616.1014721339770.0102.0431.6290.0102.0431.10SchParnesene9384.417.7114461453770.001.540.0102.04731.6290.0102.04731.10Schwahr10017.9214631465771.461465770.1002.04731.6290.0102.0471.110Schwahr10017.9214631465771.461465710.0102.07470.1012.0471.110Schwahr10010.940.101.5720.0101.5720.0102.5740.101Schwahr112991515621562170.1031.5720.0102.5740.103Schwahr129915156215621562156210.2021.1630.1012.7470.107Schwahr2001299151211210.2021.1630.1030.1730.0102.5740.105Schwahr2002481352156215647 <th< td=""><td>Benzoic acid. 4-chloro</td><td>139</td><td>91.3</td><td>15.69</td><td>NA</td><td>1337</td><td></td><td></td><td>0.418</td><td></td><td>-0.078</td><td></td><td>0.171</td><td>-0.312</td><td>3.358</td></th<>	Benzoic acid. 4-chloro	139	91.3	15.69	NA	1337			0.418		-0.078		0.171	-0.312	3.358
Berzenescerande9287.616.8014121399770.3761.1020.6390.7470.010-2.938-0.293 $2(sh)$ Farmesene9384.417.711446145377-0.0930.879-0.4731.6290.010-2.938-0.1190 $2(sh)$ Farmesene9384.417.711446145377-0.1930.879-0.4731.6390.7470.010-2.747-1.144 $2(sh)$ Farmesene9387.591.117.921463146577-1.414 $2(sh)$ Farmesene9376.019.49149215621562770.010-2.747-1.144 $Cyclohexaei, 1-ethenyl-1-9376.019.49149215621562770.1911.5720.010-2.747-1.414Cyclohexaei, 1-ethenyl-1-9376.019.49149215621562770.1911.7120.010-2.747-1.414Cyclohexaei, 1-ethenyl-1-9376.01151215621564770.1911.1290.010-2.747-1.130Cyclohexaei, 1-ethenyl-1-9372.924.79NA191570.1911.1290.010-2.742-1.217Pyridine, 2-hexyl16886.820.091513159870.1911.1290.015-2.794-1.217Pyridine, 2-hexyl168$	Benzemented9287.616.8014121339770.3761.1020.6390.7470.010-2.938-0.293-0.03 $cish$ Pannesene9384.417.71144614537700.0001.1540.010-2.037-11190 $cish$ Pannesene9384.417.71144614537700.0001.5720.010-2.033-0.143 5 -hey/dihydro8591.117.9214631465770.8001.1540.010-2.747-1.140 5 -hey/dihydro8591.117.9214631465770.8001.5720.010-2.747-1.141 5 -hey/dihydro9376.019.49149215621562770.4331.0960.0001.5720.010-2.674-0.999 $Cyclohexare, 1-ethenyl-1-9376.019.491492156215627771.141Cyclohexare, 1-ethenyl-1-9372.994.519.531562156470.010-2.674-0.999Doderande circl12994.519.5315621564770.2021.1630.010-2.747-1.217Doderande circl12994.519.5315621564700.2021.1630.010-2.744-0.999Doderande circl12994.519.131582$	<i>n</i> -Decanoic acid	73	85.5	16,12	1387	1361			0.529		0.763		0.610	-0.945	2.131
Constrained cis/Parnesen3284.417.7014461453779.0002.0179.0002.0179.0002.0179.0002.0179.0002.0179.0002.0179.0009.0002.0179.0009.00	Construction 32 8.44 17.71 14.6 14.3 14.6 14.3 14.6 14.3 14.6 14.3 14.6 14.3 16.5 0.003 0.879 0.003 0.879 0.001 -2.747 -1.144 5 -becylding/dro 85 91.1 17.92 1465 1562 7 0.003 0.879 0.001 -2.077 -1.144 5 -becylding/dro 85 91.1 17.92 1492 1562 7 0.003 1.572 0.010 -2.074 -0.999 66 -beconder 85 91.1 17.92 1492 1562 7 0.133 1.096 0.000 1.572 0.010 -2.747 -1.144 1 -methyle- $7(-methylehenyl)-4$ 129 94.5 1953 1562 1754 0.010 -2.747 -0.959 17 -methyle- 16 128 86.8 20.09 1515 0.010 -2.747 -1.2	Benzenescetsmide	00	0.00 07 6	16 80	1110	1300	÷		0 376		0.630		010	-7 039	
Current (37)S91.117.9214631465710.0001.1540.4101.9640.010-2.747-1.1405-heyldlilydro8591.117.9214631465770.8001.1540.4101.9640.010-2.747-1.1415-heyldlilydroCyclohexane, 1-ethenyl-19376.019.49149215621564700.2021.1630.0001.5720.010-2.747-1.1400.rethyl-2(1-methylethenyl)4-12994.519.53156215647700.2021.1630.0201.1570.010-2.747-1.1470.rethyl-2(1-methylethenyl)4-12994.519.53156215647700.1911.1290.010-2.744-1.2471(1-methylethenyl)4-12994.519.5315621564770.1911.1290.010-2.744-1.2471(1-methylethenyl)12994.519531564700.1911.1290.010-2.744-1.247Pordecanoic acid2.heyl72.924.79NA191570.1911.1290.010-2.734-1.247Pyridine, 2-heyl15473.024.79NA191570.3791.4130.1070.7380.0192.777-0.115Pyridine, 2-heyl739.2591.4130.1070.7380.0301.124	2(34)7(1)117.9214631465711.0001.0071.001 <td>rie-A-Enmacana</td> <td>20</td> <td>0.10</td> <td>17 71</td> <td>9777</td> <td>1460</td> <td>- +</td> <td>÷</td> <td>0.002</td> <td></td> <td>0 472</td> <td></td> <td>010</td> <td>1000 C</td> <td>1 100</td>	rie-A-Enmacana	20	0.10	17 71	9777	1460	- +	÷	0.002		0 472		010	1000 C	1 100
$ \begin{array}{l lllllllllllllllllllllllllllllllllll$	2(37)-Futatione,5391.117.92140314051405140514051405140514051.0411.1.040.010-2.747-1.4145-heyflighton5-heyflighton16015720.19414921562770-2.674-0.999Gyclohexanci12994.519.4914921562770-2.674-0.909-2.674-0.999Gyclohexanci12994.519.3315621564700-2.7320.010-2.674-0.999Pyridine, 3methyl-2-fl-methylethenyl)12994.519.5315621564700-1.1210-0.126Pyridine, 3methyl-2-fl-myl16886.820.0915131598700-2.794-1.217Pyridine, 2-hexyl9372.924.79NA1915700.7450.019-2.280-0.126Pyridine, 2-hexyl9372.924.79NA191570.7450.9190.033-1.2170.136Pyridine, 2-hexyl9372.024.8819081921700.7450.1070.7380.019-2.794-1.217Pyridine, 2-hexyl0.840.3224.791.1120.0102.280-0.126PyridinePyridine, 2-hexyl0.849.227.69217021110.0511.6170.7380.039-3.777-0.13	COTT THILSOIL		+.+O	T / · / T	0441	1100	- •	_	0000		110		0101	10.7	1.110
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	z bordanone,	CQ	1.16	11.92	1403	1400	_		0.800		0.410		010.0	-2./4/	-1.414
Cycloneary, 1-ethenyl-1- 93 7.6.0 19.49 1492 1562 7 7 0.433 1.096 0.090 1.572 0.010 -2.674 -0.999 nethyl-2-(1-methylethenyl)-4- 129 94.5 19.53 1564 7 0 20.202 1.163 -0.208 1.1713 0.010 -2.674 -0.945 Dodecanoic acid 129 94.5 19.53 15364 7 0 0.191 1.129 -0.151 1.713 0.010 -2.794 -1.217 Pyridine, 3-methyl-2-phenyl 168 86.8 20.09 1513 1598 7 0 0.191 1.129 -0.151 1.713 0.010 -2.794 -1.217 Pyridine, 2-hexyl 93 72.9 24.79 NA 1915 7 0.745 0.919 0.450 1.124 0.019 -2.280 -0.126 Pyriolo[1,2-a]pyrazine-1,4- 154 73.0 24.79 NA 1921 7 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Pyriolo[1,2-a]pyrazine-1,4- <	Cyclonexare, 1-ethenyl-1- 93 76.0 19.49 1492 1562 7 7 0.433 1.096 0.090 1.572 0.010 -2.674 -0.999 methyl-2-(1-methylethenyl)-4- 129 94.5 19.53 1564 7 0 0.202 1.163 -0.208 1.177 0.010 -2.674 -0.999 nethyl-2-(1-methylethenyl) 129 94.5 19.53 1564 7 0 0.202 1.163 -0.208 1.177 0.010 -2.794 -1.217 Pyridine, 3-methyl-2-phenyl 168 86.8 20.09 1513 1592 7 0.191 1.129 -0.151 1.713 0.010 -2.794 -1.217 Pyridine, 2-hexyl 93 72.9 24.88 1908 1921 7 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Pyrrolo[1,2-a]pyrazine-1,4- 154 73.0 24.88 1908 1921 7 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 dione, hexahydro-3-(2- 0.324 </td <td>o-nexyminyaro</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>000</td> <td></td> <td></td> <td></td> <td>0</td>	o-nexyminyaro										000				0
$ \begin{array}{l lllllllllllllllllllllllllllllllllll$	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	Cyclohexane, 1-ethenyl-1-	93	76.0	19.49	1492	1562	←	←	0.433		060.0		010.0	-2.674	-0.999
		methyl-2-(1-methylethenyl)-4-														
$ \begin{array}{llllllllllllllllllllllllllllllllllll$	$ \begin{array}{llllllllllllllllllllllllllllllllllll$	(1-methylethylidene)														
Pyridine, 3-methyl-2-phenyl16886.820.0915131598 \uparrow \uparrow 0.191 1.129 -0.151 1.713 0.010 -2.794 -1.217 Pyridine, 2-hexyl9372.924.79NA1915 \uparrow 0.745 0.919 0.450 1.124 0.019 -2.280 -0.126 Pyrrolo[1,2-d]pyrazine-1,4-15473.024.8819081921 \uparrow 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Pyrrolo[1,2-d]pyrazine-1,4-15473.024.8819081921 \uparrow 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Pyrrolo[1,2-d]pyrazine-1,4-15473.024.8819081921 \uparrow 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Pyrrolo[1,2-d]pyrazine-1,4-15473.024.8819081921 \uparrow 0.191 -2.280 -0.126 Pyrrolo[1,2-d]pyrazine-1,4-15473.024.79 0.191 0.107 0.38 -3.777 -0.113 Identifyloroyl)28492.527.6921702111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Octadecanoic acid28492.527.6921702111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha <$	Pyridine, 3-methyl-2-phenyl16886.820.0915131598 \uparrow \uparrow 0.191 1.129 -0.151 1.713 0.010 -2.794 -1.217 Pyridine, 2-hexyl9372.924.79NA1915 \uparrow 0.745 0.919 0.450 1.124 0.019 -2.280 -0.126 Pyrrolo[1,2-a]pyrazine-1,4-15473.024.8819081921 \uparrow 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 dione, hexahydro-3-(2-methylpropyl)28492.527.6921702111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 octadecanoic acid28492.527.6921702111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based on non-polar collary column stationary phase (references in Table S1 ⁴).	Dodecanoic acid	129	94.5	19.53	1562	1564	←		0.202	1.163	-0.208		0.010	-3.492	-0.455
Pyridine, 2-hexyl9372.924.79NA1915 \uparrow 0.7450.9190.4501.124 0.019 -2.280-0.126Pyrrolo[1,2-a]pyrazine-1,4-15473.024.8819081921 \uparrow 0.3791.4130.1070.738 0.038 -3.777-0.113dione, hexahydro-3-(2-methylpropyl)Octadecanoic acid28492.527.69217021110.0511.0540.3220.2680.476-1.2522.544Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based	Pyridine, 2-hexyl 93 72.9 24.79 NA 1915 1 0.745 0.919 0.450 1.124 0.019 -2.280 -0.126 Pyrrolo[1,2-a]pyrazine-1,4- 154 73.0 24.88 1908 1921 1 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Qione, hexahydro-3-(2- methylpropyl) 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 Methylpropyl) 284 92.5 27.69 2170 2111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based on non-polar capillary column stationary phase (references in Table S1 ⁴).	Pyridine, 3-methyl-2-phenyl	168	86.8	20.09	1513	1598	←	←	0.191		-0.151		0.010	-2.794	-1.217
Pyrrolo[1,2-a]pyrazine-1,4- 154 73.0 24.88 1908 1921 \uparrow 0.379 1.413 0.107 0.38 -3.777 -0.113 dione, hexahydro-3-(2- methylpropyl) 0.379 1.413 0.107 0.38 -3.777 -0.113 dione, hexahydro-3-(2- methylpropyl) 0.051 1.054 0.268 0.476 -1.252 2.544 Octadecanoic acid 284 92.5 27.69 2111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based	Pyrrolo[1,2-a]pyrazine-1,4- 154 73.0 24.88 1908 1921 \uparrow 0.379 1.413 0.107 0.38 -3.777 -0.113 dione, hexahydro-3-(2- methylpropyl) 0.379 1.413 0.107 0.738 0.038 -3.777 -0.113 dione, hexahydro-3-(2- methylpropyl) 0.051 1.054 0.268 0.476 -1.252 2.544 Octadecanoic acid 284 92.5 27.69 2111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based on non-polar capillary column stationary phase (references in Table S1 ^a).	Pvridine. 2-hexvl	93	72.9	24.79	NA	1915	• ←		0.745		0.450		0.019	-2.280	-0.126
dione has ally methylproperties at the statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based	(α) (a) (b) (b) (b) (b) (b) (b) (b) (b) (b) (b	Pvrrolo[1_2-a]nvrazine-1_4-	154	73.0	24.88	1908	1921			0 379		0.107		038	-3 777	-0.113
α methylpropyl) (2.5 27.69 2170 2111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Octadecanoic acid 2.84 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based	α methylpropyl) (24 methylpropyl) (284 92.5 27.69 2170 2111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 0.310 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^{<i>a</i>} Identified to metabolomics standards initiative level 1. ^{<i>b</i>} NIST library retention indices based on non-polar column stationary phase (references in Table S1 ⁺).	dione hevehodro-3-(2-	1					_								
$\frac{1}{1000}$ 1	$\frac{1}{1000}$ Octadecanoic acid 284 92.5 27.69 2170 2111 0.051 1.054 0.322 0.268 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^{<i>a</i>} Identified to metabolomics standards initiative level 1. ^{<i>b</i>} NIST library retention indices based on non-polar capillary column stationary phase (references in Table S1 ⁺).	mothy invarigue														
Octadecanoic acid 284 92.5 27.69 21.0 21.1 0.051 1.054 0.322 0.328 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based	Octadecanoic acid 284 92.5 27.69 21.70 21.11 0.051 1.054 0.522 0.508 0.476 -1.252 2.544 Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based on non-polar collary column stationary phase (references in Table S1 ⁴).															
Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based	Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). ^a Identified to metabolomics standards initiative level 1. ^b NIST library retention indices based on non-polar capillary column stationary phase (references in Table S1 ⁺).	Octadecanoic acid	284	92.5	27.69	2170	2111					0.322		.476	-1.252	2.544
Values highlighted in Bold indicate statistically significant changes in abundance ($\alpha < 0.05$). "Identified to metabolomics standards initiative level 1. "NIST library retention indices based	Values nighlighted in Bold indicate statistically significant changes in abundance (α < 0.05). "Identified to metabolomics standards initiative level 1. "NIST library retention indices based on non-bolar capillary column stationary phase (references in Table S1 ⁺).		•		•	-					•	y	111		:	-
	on non-bolar capillary column stationary phase (references in Table S1†).	Values highlighted in Bold ind	licate statistica	ally signific	ant changes ir	abundanc	$\alpha < 0.05$). "I	dentified to me	etabolomics sta	ndards ini	tiative le	vel 1. [~] N	IST librar	y reten	tion indic	es based

Analyst




Fig. 5 Boxplots of VOCs which are significantly different between infected and uninfected cells, showing all sample groups for comparison. Dashed line represents peak intensity mean after z-normalisation.

clinically useful diagnostic biomarker. However, further optimisation of the method (*e.g.* use of labelled sulfur-containing amino acids to track DMDS) is required to evaluate metabolic changes during infection. Culture conditions could be further improved by using primary cell culture, other cell types, by targeting specific bacterial and mammalian growth phases, and by collecting VOCs through dynamic or active sampling which has the advantage of measuring VOC metabolism in relation to VOC release time and rate.^{33,34} Finally, we recognise the use of immortalised mammalian cells lines such as A549 may not represent normal mammalian cell metabolism and response to infection and a more representative model would include patient-derived primary cells.

We demonstrated for the first time a direct VOC sampling method for ALI cultures of bacterial infection and using standard 2D culture well inserts. TFME is a highly versatile method^{31,35} and was applied to ALI cultures with minimal intervention, thus preserving routine mammalian lung cell propagation techniques. ALI culture is physiologically relevant and resembles the environment of the respiratory epithelium more closely than standard sedimented liquid cultures. Furthermore, ALI is an important tool to study the effects of nebulised drugs, exogenous pollutants and particulate matter on airway cells. Cultures can be further enhanced to develop a true lung infection model to include bronchial epithelial cells for cilia, goblet cells for mucus production, and include inflammatory cells for host response to xenobiotics.³⁶

5. Conclusions

In this study we have detected VOCs characteristic of *S. aureus* infection in lung epithelial cells, using a novel approach which harnesses the adaptability of TFME to sample from a two-dimensional air-liquid interface culture model. We identified VOCs that are unique to *S. aureus*, and to infected and uninfected mammalian cells. These results demonstrate the poten-

tial for investigating VOCs as potential biomarkers of infection using complex two-dimensional culture models.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

We acknowledge the experimental support provided by Kai Wang and Professor Clare Mills at the Manchester Institute of Biotechnology and Dr John Blaikley and Dr Conal Hayton for donation of the immortalised cell line. E. B. also acknowledges the fellowship support of the European Cystic Fibrosis Society. W. A. and S. J. F. are supported by the NIHR-Manchester Biomedical Research Centre.

References

- A. J. Fischer, S. B. Singh, M. M. LaMarche, L. J. Maakestad, Z. E. Kienenberger, T. A. Peña, *et al.*, Sustained Coinfections with Staphylococcus aureus and Pseudomonas aeruginosa in Cystic Fibrosis, *Am. J. Respir. Crit. Care Med.*, 2021, 203(3), 328–338.
- 2 J. Vincent, J. Rello, J. Marshall, E. Silva, A. Anzueto, C. Martin, *et al.*, International Study of the Prevalence and Outcomes of Infection in Intensive Care Units, *J. Am. Med. Assoc.*, 2009, **302**(21), 2323–2329.
- 3 D. Koulenti, E. Tsigou and J. Rello, Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study, *Eur. J. Clin. Microbiol. Infect. Dis.*, 2017, 36(11), 1999– 2006.
- 4 D. G. Wootton, S. J. Aston and T. W. Felton, The challenge of antimicrobial prescribing for hospital-acquired pneumonia, *J. Hosp. Infect.*, 2020, **104**(2), 198–199.
- 5 W. M. Ahmed, O. Lawal, T. M. Nijsen, R. Goodacre and S. J. Fowler, Exhaled Volatile Organic Compounds of Infection: A Systematic Review, *ACS Infect. Dis.*, 2017, 3(10), 695–710.
- 6 L. D. J. Bos, P. J. Sterk and M. J. Schultz, Volatile Metabolites of Pathogens: A Systematic Review, *PLoS Pathog.*, 2013, 9(5), e1003311.
- 7 A. H. Neerincx, B. P. Geurts, M. F. J. Habets, J. A. Booij, J. van Loon, J. J. Jansen, *et al.*, Identification of Pseudomonas aeruginosa and Aspergillus fumigatus mono- and co-cultures based on volatile biomarker combinations, *J. Breath Res.*, 2016, **10**(1), 016002.
- 8 M. Nasir, H. D. Bean, A. Smolinska, C. A. Rees, E. T. Zemanick and J. E. Hill, Volatile molecules from bronchoalveolar lavage fluid can 'rule-in' Pseudomonas aeruginosa and 'rule-out' Staphylococcus aureus infections in cystic fibrosis patients, *Sci. Rep.*, 2018, **8**(1), 1–11.
- 9 W. Filipiak, R. Beer, A. Sponring, A. Filipiak, C. Ager, A. Schiefecker, *et al.*, Breath analysis for in vivo detection of

pathogens related to ventilator-associated pneumonia in intensive care patients: a prospective pilot study, *J. Breath Res.*, 2015, 9(1), 016004.

- 10 C. L. Jenkins and H. D. Bean, Influence of media on the differentiation of Staphylococcus spp. By volatile compounds, *J. Breath Res.*, 2020, **14**(1), 016007.
- 11 O. Lawal, H. Muhamadali, W. M. Ahmed, I. R. White, T. M. E. Nijsen, R. Goodacre, *et al.*, Headspace volatile organic compounds from bacteria implicated in ventilatorassociated pneumonia analysed by TD-GC/MS, *J. Breath Res.*, 2018, **12**(2), 026002.
- 12 J. Zhu, H. D. Bean, M. J. Wargo, L. W. Leclair and J. E. Hill, Detecting bacterial lung infections: in vivo evaluation of in vitro volatile fingerprints, *J. Breath Res.*, 2013, 7(1), 016003.
- 13 H. D. Bean, J. Jimenez-Diaz, J. Zhu and J. E. Hill, Breathprints of model murine bacterial lung infections are linked with immune response, *Eur. Respir. J.*, 2015, **45**(1), 181–190.
- S. Traxler, G. Barkowsky, R. Saß, A. C. Klemenz, N. Patenge, B. Kreikemeyer, *et al.*, Volatile scents of influenza A and S. pyogenes (co-)infected cells, *Sci. Rep.*, 2019, 9(1), 1–12.
- 15 O. Lawal, H. Knobel, H. Weda, L. D. Bos, T. M. E. Nijsen, R. Goodacre, *et al.*, Volatile organic compound signature from co- culture of lung epithelial cell line with Pseudomonas aeruginosa, *Analyst*, 2018, 3148–3155.
- 16 D. Baldassi, B. Gabold and O. M. Merkel, Air–Liquid Interface Cultures of the Healthy and Diseased Human Respiratory Tract: Promises, Challenges, and Future Directions, *Adv. Biomed. Res.*, 2021, 1(6), 2000111.
- 17 M. Schivo, A. A. Aksenov, A. L. Linderholm, M. M. McCartney, J. Simmons, R. W. Harper, *et al.*, Volatile emanations from in vitro airway cells infected with human rhinovirus, *J. Breath Res.*, 2014, 8(3), 037110.
- 18 M. S. Yamaguchi, M. M. McCartney, A. L. Linderholm, S. E. Ebeler, M. Schivo and C. E. Davis, Headspace sorptive extraction-gas chromatography-mass spectrometry method to measure volatile emissions from human airway cell cultures, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2018, **1090**(January), 36–42.
- 19 M. S. Yamaguchi, M. M. McCartney, A. K. Falcon, A. L. Linderholm, S. E. Ebeler, N. J. Kenyon, *et al.*, Modeling cellular metabolomic effects of oxidative stress impacts from hydrogen peroxide and cigarette smoke on human lung epithelial cells, *J. Breath Res.*, 2019, **13**(3), 036014.
- 20 M. Ashrafi, Y. Xu, H. Muhamadali, I. White, M. Wilkinson, K. Hollywood, *et al.*, A microbiome and metabolomic signature of phases of cutaneous healing identified by profiling sequential acute wounds of human skin: An exploratory study, *PLoS One*, 2020, **15**(2), e0229545.
- 21 W. M. Ahmed, P. Geranios, I. R. White, M. Bromley, O. Lawal, T. Nijsen, *et al.*, Development of an adaptable headspace sampling method for metabolic profiling of the fungal volatome, *Analyst*, 2018, 4155–4162.

- L. W. Sumner, A. Amberg, D. Barrett, M. H. Beale, R. Beger, C. A. Daykin, *et al.*, Proposed minimum reporting standards for chemical analysis, *Metabolomics*, 2007, 3(3), 211–221.
- 23 J. J. Grandy, E. Boyaci and J. Pawliszyn, Development of a Carbon Mesh Supported Thin Film Microextraction Membrane As a Means to Lower the Detection Limits of Benchtop and Portable GC/MS Instrumentation, *Anal. Chem.*, 2016, **88**(3), 1760–1767.
- 24 M. R. Kiedrowski, A. E. Paharik, L. W. Ackermann, A. U. Shelton, S. B. Singh, T. D. Starner, *et al.*, Development of an in vitro colonization model to investigate Staphylococcus aureus interactions with airway epithelia, *Cell. Microbiol.*, 2016, **18**(5), 720–732.
- 25 G. Preti, E. Thaler, C. W. Hanson, M. Troy, J. Eades and A. Gelperin, Volatile compounds characteristic of sinusrelated bacteria and infected sinus mucus: Analysis by solid-phase microextraction and gas chromatography-mass spectrometry, *J. Chromatogr. B: Anal. Technol. Biomed. Life Sci.*, 2009, **877**(22), 2011–2018.
- 26 R. Thriumani, A. Zakaria, Y. Z. H. Y. Hashim, A. I. Jeffree, K. M. Helmy, L. M. Kamarudin, *et al.*, A study on volatile organic compounds emitted by *in vitro* lung cancer cultured cells using gas sensor array and SPME-GCMS, *BMC Cancer*, 2018, **18**(1), 1–17.
- 27 C. N. H. Marques, D. G. Davies and K. Sauer, Control of biofilms with the fatty acid signaling molecule cis-2-Decenoic acid, *Pharmaceuticals*, 2015, 8(4), 816–835.
- 28 D. G. Davies and C. N. H. Marques, A fatty acid messenger is responsible for inducing dispersion in microbial biofilms, *J. Bacteriol.*, 2009, **191**(5), 1393–1403.
- 29 M. W. Frank, S. G. Whaley and C. O. Rock, Branched-chain amino acid metabolism controls membrane phospholipid

structure in Staphylococcus aureus, J. Biol. Chem., 2021, 297(5), 1-14.

- 30 X. Chen, W. Ping Teoh, M. R. Stock, Z. J. Resko and F. Alonzo, Branched chain fatty acid synthesis drives tissuespecific innate immune response and infection dynamics of Staphylococcus aureus, *PLoS Pathog.*, 2021, 17(9), 1–22.
- 31 W. Filipiak, K. Jaroch, P. Szeliska, K. Żuchowska and B. Bojko, Application of thin-film microextraction to analyze volatile metabolites in a549 cancer cells, *Metabolites*, 2021, 11(10), 704.
- 32 V. Kapishon, G. K. Koyanagi, V. Blagojevic and D. K. Bohme, Atmospheric pressure chemical ionization mass spectrometry of pyridine and isoprene: potential breath exposure and disease biomarkers, *J. Breath Res.*, 2013, 7(2), 026005.
- 33 A. Baranska, A. Smolinska, A. W. Boots, J. W. Dallinga and F. J. van Schooten, Dynamic collection and analysis of volatile organic compounds from the headspace of cell cultures, *J. Breath Res.*, 2015, **9**(4), 047102.
- 34 W. M. Ahmed, P. Geranios, I. R. White, M. Bromley, O. Lawal, T. Nijsen, *et al.*, Development of an adaptable headspace sampling method for metabolic profiling of the fungal volatome, *Analyst*, 2018, **143**, 4155–4162.
- 35 T. Koehler, I. Ackermann, D. Brecht, F. Uteschil, J. Wingender, U. Telgheder, *et al.*, Analysis of volatile metabolites from in vitro biofilms of Pseudomonas aeruginosa with thin-film microextraction by thermal desorption gas chromatography-mass spectrometry, *Anal. Bioanal. Chem.*, 2020, **412**(12), 2881–2892.
- 36 V. V. Thacker, N. Dhar, K. Sharma, R. Barrile, K. Karalis and J. D. McKinney, A lung-on-chip infection model reveals protective and permissive roles of alveolar epithelial cells in tuberculosis, *bioRxiv*, 2020.